OR WAIT 15 SECS
Phase Forward Signs Multi-Year, Multi-Million Dollar Agreement with Novo Nordisk to Expand Use of InForm EDC Product Across All Clinical Trial Phases.
WALTHAM, Mass.--(BUSINESS WIRE <http://www.businesswire.com/> )--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year, multi-million dollar enterprise license and services agreement with Novo Nordisk, expanding the existing relationship between the two companies. Novo Nordisk plans to use Phase Forward’s InForm™ electronic data capture (EDC) product as the default data capture system across all clinical trial phases, from Phases I through IV.
Since signing an application service provider (ASP) arrangement in mid-2006, Novo Nordisk has successfully implemented and integrated global InForm studies with internal systems. Novo Nordisk is currently using InForm to support trials in more than 30 countries.
“We’ve had a very successful collaboration with Phase Forward over the last three years, and look forward to expanding the relationship,” said Henrik Lynge, Head of Clinical System Management in Novo Nordisk. “InForm’s ability to easily integrate with other in-house systems and the product’s scalability have been crucial to the implementation, enabling our team to streamline data collection for complex studies spanning multiple geographies.”
“Novo Nordisk is a global leader in diabetes care,” said Bob Weiler, chairman and CEO of Phase Forward. “We’re pleased to be supporting their efforts to constantly advance the treatment options for a disease that affects quality of life for millions of people worldwide.”
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm™), phase I clinic automation (LabPas™), clinical data management (Clintrial™), clinical trials signal detection (CTSD™), strategic pharmacovigilance (Empirica Signal™) and Signal Management, adverse event reporting (Empirica Trace™), applied data standards (WebSDM™), Web-integrated interactive response technologies (Clarix™), and clinical data analysis and reporting automation and compliance (Waban SCE/CDR, Waban SMS and Waban LIMS). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com <http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.phaseforward.com&esheet=5948518&lan=en_US&anchor=www.phaseforward.com&index=1> .
Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward’s products and services, demand for Phase Forward’s products and services, future business and operations plans of a Phase Forward customer, and the ability of this Phase Forward’s customers to realize benefits from the use of Phase Forward’s products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward’s customers to realize benefits from the use of its products and services, the possibility that customers’ needs or plans may change over time, and the possibility that the level of demand for Phase Forward’s products and services may vary. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.